{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:53:36Z","timestamp":1791388416333,"version":"4.3.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":260,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-Gilead2024-PT-0006"],"award-info":[{"award-number":["Y-Gilead2024-PT-0006"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515012742"],"award-info":[{"award-number":["2025A1515012742"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82504161"],"award-info":[{"award-number":["82504161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573692"],"award-info":[{"award-number":["82573692"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although radiotherapy (RT) remains the standard of care for locally advanced colorectal cancer (CRC), intrinsic and acquired resistance frequently compromise long-term outcomes. Sacituzumab govitecan (SG)\u2014a TROP2-directed antibody\u2013drug conjugate\u2014offers a targeted platform for intracellular SN-38 delivery. The aim of the present preclinical study was to investigate whether SG enhances radiosensitivity in CRC, thereby providing a preclinical rationale for the clinical evaluation of SG-based combination strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated SG\u2013RT synergy across CRC cell lines with differential TROP2 expression (SW480, DLD-1 vs SW620, HCT116). In mechanistic studies, clonogenic assays, flow cytometry, cell counting kit-8, Western blot, and comet assays were utilized to assess cell survival, apoptosis, and DNA damage. TROP2 was knocked down or overexpressed to validate its role in radiosensitization. In vivo efficacy was evaluated by using cell-line-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models. Immunohistochemistry for cleaved caspase-3 (CASP3), phosphorylated histone H2AX (\u03b3-H2AX), and Ki-67 were used to assess treatment-induced biological effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In TROP2-high CRC cell lines (SW480, DLD-1), combined SG and RT markedly inhibited proliferation, increased apoptosis, and amplified DNA double-strand breaks, as evidenced by elevated \u03b3-H2AX expression and comet assay tail moments. Knockdown of TROP2 abrogated this synergy, whereas TROP2 overexpression restored it. In CDX and PDX models, SG combined with RT significantly suppressed tumor growth, increased cleaved CASP3 and \u03b3-H2AX expression, and reduced Ki-67 without exacerbating systemic weight loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings identify SG as a potent radiosensitizer, providing a strong rationale for integrating SG into neoadjuvant RT regimens for locally advanced CRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/gastro\/goag101","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:51:49Z","timestamp":1788616309000},"source":"Crossref","is-referenced-by-count":0,"title":["Synergistic effects of sacituzumab govitecan and radiotherapy in preclinical models of colorectal cancer"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1863-1008","authenticated-orcid":false,"given":"Ruowei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingting","family":"Situ","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Shenzhen Second People\u2019s Hospital, The First Affiliated Hospital of Shenzhen University , Shenzhen 518035,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, Zhujiang Hospital of Southern Medical University , Guangzhou, Guangdong 510282,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songran","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4703-3486","authenticated-orcid":false,"given":"Weili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4593-4264","authenticated-orcid":false,"given":"Weihao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3694-0830","authenticated-orcid":false,"given":"Zhenhai","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-8195","authenticated-orcid":false,"given":"Jianhong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , 651 Dongfeng Road East , Guangzhou, Guangdong 510060,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"2026100711064753300_goag101-B1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"2026100711064753300_goag101-B2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026100711064753300_goag101-B3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"2026100711064753300_goag101-B4","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N Engl J Med"},{"key":"2026100711064753300_goag101-B5","doi-asserted-by":"publisher","first-page":"goae050","DOI":"10.1093\/gastro\/goae050","article-title":"Tumor regression pattern may impact the prognosis of rectal cancer patients with tumor regression grade 1 after neoadjuvant chemoradiotherapy","volume":"12","author":"Tang","year":"2024","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2026100711064753300_goag101-B6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3760\/cma.j.cn441530-20230107-00010","article-title":"[Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)]","volume":"26","author":"Wang","year":"2023","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"2026100711064753300_goag101-B7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.6061\/clinics\/2016(08)07","article-title":"Clinical factors of post-chemoradiotherapy as valuable indicators for pathological complete response in locally advanced rectal cancer","volume":"71","author":"Peng","year":"2016","journal-title":"Clinics (Sao Paulo)"},{"key":"2026100711064753300_goag101-B8","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1200\/JCO.20.01932","article-title":"Multicenter, randomized, phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer","volume":"38","author":"Zhu","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026100711064753300_goag101-B9","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026100711064753300_goag101-B10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40779-018-0167-4","article-title":"Biological effects of radiation on cancer cells","volume":"5","author":"Wang","year":"2018","journal-title":"Mil Med Res"},{"key":"2026100711064753300_goag101-B11","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-24-1525","article-title":"The mode of action and clinical outcomes of sacituzumab govitecan in solid tumors","volume":"31","author":"Tolaney","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026100711064753300_goag101-B12","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMra1608986","article-title":"Recent developments in radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"N Engl J Med"},{"key":"2026100711064753300_goag101-B13","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie Du Sert","year":"2020","journal-title":"PLoS Biol"},{"key":"2026100711064753300_goag101-B14","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/cancers16091649","article-title":"The safety and efficacy of the combination of sacituzumab govitecan and palliative radiotherapy\u2014a retrospective multi-center cohort study","volume":"16","author":"Krug","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026100711064753300_goag101-B15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2024.03.013","article-title":"Activity of enfortumab vedotin and sacituzumab govitecan with radiation in preclinical models of bladder cancer","volume":"86","author":"Zhou","year":"2024","journal-title":"Eur Urol"},{"key":"2026100711064753300_goag101-B16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"key":"2026100711064753300_goag101-B17","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.34172\/jlms.2022.09","article-title":"Effects of radiotherapy in combination with irinotecan and 17-AAG on bcl-2 and caspase 3 gene expression in colorectal cancer cells","volume":"13","author":"Ebrahimpour","year":"2022","journal-title":"J Lasers Med Sci"},{"key":"2026100711064753300_goag101-B18","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/cac2.70058","article-title":"Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial","volume":"45","author":"Zhang","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"2026100711064753300_goag101-B19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.18632\/oncotarget.1719","article-title":"Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing","volume":"5","author":"Gameiro","year":"2014","journal-title":"Oncotarget"},{"key":"2026100711064753300_goag101-B20","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"2026100711064753300_goag101-B21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41590-019-0561-4","article-title":"Immunological impact of cell death signaling driven by radiation on the tumor microenvironment","volume":"21","author":"Rodriguez-Ruiz","year":"2020","journal-title":"Nat Immunol"},{"key":"2026100711064753300_goag101-B22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"2026100711064753300_goag101-B23","doi-asserted-by":"publisher","first-page":"1074477","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"2026100711064753300_goag101-B24","doi-asserted-by":"publisher","first-page":"1632705","DOI":"10.3389\/fimmu.2025.1632705","article-title":"Another power of antibody-drug conjugates: Immunomodulatory effect and clinical applications","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"key":"2026100711064753300_goag101-B25","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ijrobp.2025.11.060","article-title":"Multicenter retrospective analysis of the safety and efficacy of sacituzumab govitecan combined with radiation therapy: the French ATTENTION study","volume":"125","author":"Alati","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag101\/71666214\/goag101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag101\/71666214\/goag101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:06:56Z","timestamp":1791385616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goag101\/8875833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goag101","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,20]]},"article-number":"goag101"}}